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Summary of the thesis 
Introduction: Bisphosphonate-related osteonecrosis of the jaws is considered to be a rare but 
severe complication of bisphosphonate therapy. The presumably multifactorial 
pathomechanisms of medication-related osteonecrosis of the jaws have not been fully 
elucidated so far. To understand this condition better data collection is essential. Although the 
number of scientific papers about this subject is large, only a few multicenter reports have been 
published. Management of this serious side effect is a real challenge and requires a 
multidisciplinary approach.  
Material and methods: We present a novel cloud-based data collection system for the 
evaluation of the risk factors of bisphosphonate-related osteonecrosis of the jaws. Web-based 
questionnaire and database have been set up and made available to voluntary researchers and 
clinicians in oral and maxillofacial surgery in Hungary and Slovakia.  
Results: To date, fifteen colleagues from eight maxillofacial units have joined the study. Data 
of 180 patients have been recorded. Collected data were statistically analysed and evaluated 
from an epidemiological point of view.    
Discussions: Authors consider cloud-based multicenter data collection a useful tool that allows 
for real-time collaboration between users, facilitates fast data entry and analysis, and thus 
considerably contributes to widening our knowledge of bisphosphonate-related osteonecrosis 
of the jaws. 
Conclusions: Although several issues are still open regarding the management of the disorder, 
this study may help to develop evidence-based, individualized, stage-adapted therapeutic 
strategies that will replace the previous empirical treatment. 
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I. Introduction  
 
1.1. Definition of MRONJ and its changes  
Bisphosphonates (BPs) are considered to be the “gold standard” of the treatment of some 
osteologic (osteoporosis, rheumatoid arthritis, Paget-disease) and metastatic oncologic 
diseases. BPs have an antiresorptive effect on bones and they effectively reduce pathological 
bone pain and the frequency of skeletal related events. They also decrease intraosseous tumor 
growth and tumor-induced hypercalcaemia; and finally, they improve the patient's quality of 
life. The first known cases of medication related osteonecrosis of the jaw (MRONJ) were 
published in the literature in 2003 [Marx 2003][Ruggiero 2004]. These cases have been related 
to BP treatments, therefore, this adverse drug reaction (ADR) was named bisphosphonate-
related osteonecrosis of the jaw (BRONJ) [Migliorati 2005]. The first Position Paper in this 
topic from the American Association of Oral and Maxillofacial Surgeons (AAOMS) also used 
this nomenclature [Ruggiero 2009].  
 
Definition of BRONJ (AAOMS 2009) Definition of MRONJ (AAOMS 2014) 
1. Current or previous treatment with a 
bisphosphonate 
2. Exposed bone in the maxillofacial 
region that has persisted for more than 8 
weeks 
3. No history of radiation therapy to the 
jaws 
1. Current or previous treatment with 
antiresorptive or antiangiogenic agents 
2. Exposed bone or bone that can be probed 
through an intraoral or extraoral fistula(e) in 
the maxillofacial region that has persisted for 
more than eight weeks 
3. No history of radiation therapy to the jaws or 
obvious metastatic disease to the jaws. 
Table 1. Changes in the nomenclature and definition of bisphosphonate/medication related 
osteonecrosis of the jaws.   
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Osteonecrosis of the jaw has been observed in connection with several new groups of drugs 
since 2009, so it became necessary to amend the terminology, definition and description of the 
disease. This condition has been referred to as medication-related osteonecrosis of the jaws 
(MRONJ) by the AAOMS since 2014 [Ruggiero 2009]. The changes in definition are illustrated 
in Table 1 [Vereb 2020]. 
 
1.2. Potential pathomechanisms of MRONJ  
The pathomechanism of MRONJ has not been completely clarified so far. Several hypotheses 
were imposed to elucidate the full process of osteonecrosis that develops in the maxilla or in 
the mandible. It is most likely that the multifactorial disease is a consequence of the interaction 
of drugs acting at different biochemical points of attack and signaling pathways with trigger 
factors from the external environment [Aghaloo 2016][Ikebe 2013][Otto 2010][Otto 
2015][Ristow 2014][Wat 2016]. Figure 1 shows the several local and systemic factors that are 
thought to play an important role in the development of the disease. The possible 
pathophysiological theories of MRONJ development are discussed in more detail in the 
following subsections. 
 
Figure 1. Local and systemic factors of MRONJ 
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1.2.1. Changes in bone remodelling     
Bone remodeling - a balance between bone resorption and bone formation - is a complex 
mechanism regulated by paracrine, autocrine and endocrine hormones. If this pathway is 
disturbed, different pathological conditions may develop. Antiresorptive drugs inhibit not only 
osteoclast activity directly and indirectly, but through this inhibition osteoblast-osteoclast 
coupling and thus osteoblast functional activity are also injured, as demonstrated by numerous 
studies [Aguirre 2012][Janovszky 2014][Kobayashi 2010][Yamashita 2011]. 
 
1.2.2. Inhibition of angiogenesis       
Bone regeneration depends not only on bone remodeling, but also on blood supply and 
angiogenesis. Tooth extraction related tissue ischemia initiates an inflammatory cascade, which 
promotes the expression of different hypoxia-induced angiogenic factors [Sharma 2013]. A 
considerable contribution of VEGF in the pathogenesis of MRONJ can be presumed, since 
suppression of this protein or its signaling pathway alone can provoke the development of 
MRONJ. However, antiresorptive treatment in combination with antiangiogenic drugs can 
significantly increase the incidence of this severe disorder [Aragon-Ching 2009][Mozzati 
2012][Pakosch 2012]. This theory is supported by several studies investigating antiangiogenic 
effects of bisphosphonates [Kobayashi 2010][Pabst 2014] [Wood 2002]. 
 
1.2.3. Inflammation and infection         
Local contamination and infection after invasive dental procedures in bisphosphonate-treated 
patients have also been emphasized in the pathogenesis of MRONJ [Mawardi 2011][Wei 2012]. 
Biofilm formation promoting the effect of BP’s may establish this concept [Kumar 2010] 
[Sedghizadeh 2008], but clinical experience contradicts this theory, since MRONJ can develop 
several years after tooth extraction, too.  
BP administration can upregulate the expression of pro-inflammatory cytokines (e.g. Il-1 or 
TNF-alpha), consequently an enhancement of leukocyte–endothelial cell interactions, which is 
more pronounced in the mandibular periosteum and has not been observed in any other skeletal 
location yet [Anastasilakis AD 2012][Norton JT 2011][Senel FC 2010][Yu YY 2012]. 
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1.2.4. Soft tissue toxicity          
The biological utilization significantly differs depending on the administration way of BPs. 
Gastrointestinal absorption is approximately 1%, as long as intravenous absorption is about 
60%. This is followed by binding to the bone surface [Ezra 2000], where these drugs exert their 
effect, and periosteal stem cells responsible for bone regeneration can be found [Allen 
2004][Chappuis 2012][Xie 2008].  
After prolonged use, BPs accumulate in the skeleton, and reach the highest concentration in the 
mandible. Potentially a toxic level may develop, which may affect cellular mechanism and bone 
regeneration, leading to the development of MRONJ [Açil 2012][Agis 2010][Kimmel 2007] 
[Marolt 2012] [Naidu 2008] Reid  2007][Scheper 2009]. 
 
1.2.5. Dysfunctions of immune system        
Immune system is responsible not only for defensive mechanisms against infective agents, but 
also for regenerative mechanisms. These signaling pathways can be affected by BPs in different 
manners. Clinical studies have revealed that some BPs can elevate the level of pro-
inflammatory cytokines, such as TNF-alpha [Anastasilakis 2012][Katz 2011][Tzermpos 2013], 
although interestingly it was not observed in animal studies [Janovszky 2015]. 
Polymorphonuclear leukocytes activated by inflammatory cascade showed alteration in number 
and functional activity [Hagelauer 2014] [Kuiper 2012][Salvolini 2009], which were 
investigated as a biomarker for MRONJ susceptibility [Favot 2013]. After chronic BP 
treatment, altered chemotaxis and enhanced leukocyte-endothelial interactions can be observed 
in the mandibular periosteum, presumably mediated by different degrees of endothelium-
derived adhesion molecule expression at the different anatomical locations [Janovszky 2015]. 
 
1.3. Staging and clinical appearance of MRONJ     
  
Based on the Position Paper of AAOMS 5 stages of MRONJ can be distinguished according to 
their severity [Ruggiero 2014]: 
At risk: no apparent necrotic bone in patients who have been treated with oral or intravenous 
bisphosphonates 
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Stage 0: no clinical evidence of necrotic bone but nonspecific clinical findings, radiographic 
changes, and symptoms 
Stage 1: exposed and necrotic bone or fistulas that probes to bone in patients who are 
asymptomatic and have no evidence of infection 
Stage 2: exposed and necrotic bone or fistulas that probes to bone associated with infection as 
evidenced by pain and erythema in the region of exposed bone with or without purulent 
drainage 
Stage 3: exposed and necrotic bone or a fistula that probes to bone in patients with pain, 
infection, and one of the following: exposed and necrotic bone extending beyond the region of 
alveolar bone (i.e., inferior border and ramus in mandible, maxillary sinus, and zygoma in 
maxilla) resulting in pathologic fracture, extraoral fistula, oral antral or oral nasal 
communication, or osteolysis extending to inferior border of the mandible or sinus floor (Figure 
2) 
 
Figure 2. Severe osteonecrosis of the mandible (MRONJ stage 3 caused by intravenous BP)  
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1.4. Medications causing potentially MRONJ    
As a result of modern oncologic treatments, increased life expectancies and significantly  
improved quality of life have become available to patients. However, studies have reported a 
decrease in bone density and bone loss as a result of long-term hormone ablation treatments 
(eg.: breast and prostate cancer) [Brufsky 2008]. 
In addition to bisphosphonates, other antiresorptive agents with better pharmacokinetics have 
been developed to treat these side effects [Hellstein 2011][Uyanne 2014][Van den Wyngaert 
2011]. Explosive development of biological target therapies have led to the detection of 
additional MRONJ cases in association with non-antiresorptive medications [Abel Mahedi 
Mohamed 2018][King 2019][Patel 2015]. 
 
 
 
1.4.1. Pharmacology of bisphosphonates        
Bisphosphonates (BPs) are widely used for the treatment of osteolytic conditions, such as 
osteoporosis, oncological diseases with bone metastasis or multiplex myeloma [Ruggiero 
2014]. These antiresorptive drugs are pyrophosphate analogs, where oxygen is replaced by a 
carbon atom, resulting in a stable molecule against hydrolytic enzymes. They contain two side-
chains (R1 and R2) attaching to the central carbon atom. At position R1 all BPs contain a 
hydroxyl side-group, which is responsible for the quality of binding to bone. R2 side-chain 
determines the physicochemical and biological properties of BPs, especially in case of nitrogen-
containing BPs, which are generally considered to be the most efficient antiresorptive drugs 
[Cremers 2011][Ebetino 2011][Rogers 2011].  
A distinction is made between BPs, according to the development (first- (e.g. etidronate, 
clodronate), second- (e.g. alendronate and pamidronate), third-generation (e.g. zoledronate, 
olpadronate and neridronate) compounds) or nitrogen content. Latter is clinically more relevant 
as more severe side-effects (i.e. osteonecrosis) have been attributed to BPs containing nitrogen 
[Marx 2003][Ruggiero 2004]. The therapeutic effect of BPs is linked to the inhibition of 
functional activity of osteoclasts, leading to the inhibition of bone resorption and a reduction of 
bone turnover [Brozoski 2012][Rodan 1998]. 
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The mechanism of action shows differences as a function of the nitrogen content [Luckman 
1998] [Mönkkönen 2006]. Beside their antiresorptive effect, BPs may inhibit antiangiogenic 
signaling pathway by the modification of VEGF or VEGF receptor expressions [Smidt-Hansen 
2013] [Wood 2002], the migration of different cell types, influencing regeneration [Koch 2011] 
[Ohba 2014][Ziebart 2013], and also modulate immunological processes [Kalyan 2014][Sasaki 
2013] (Figure 3).  
The therapeutic indication or the severity of skeletal disorders may determine the route of 
administration, the dose or the frequencies of BPs. Gastrointestinal absorption by paracellular 
transport is about 1%, irrespective of nitrogen content, while BPs administered intravenously 
may show 60% bioavailability [Cremers 2011][Ezra 2000]. It is well-known that BPs can affect 
bone remodeling for several years, owing to their long half-life (~ 10 years) [Brozoski 2012]. 
 
 
 
 
Figure 3.  The effects of bisphosphonates [Holen 2010] 
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1.4.2. Pharmacology of RANKL inhibitors (denosumab)      
Receptor activator of nuclear factor kappa-B ligand (RANKL) is one of the most important 
factors that regulates bone remodeling [Walsh 2014]. Denosumab is a fully human monoclonal 
antibody that specifically binds and inactivates RANKL. Denosumab has provided a 
breakthrough in the treatment of osteoporosis, multiple myeloma and solid tumors with bone 
metastases.  
By binding to RANKL, denosumab affects the key signaling pathway involved in bone 
remodeling and disrupts the cycle of bone destructions stimulated by the metastasized tumor 
cells [Chiu 2017][Tanaka 2018][Tanaka 2019][Van Dam 2019]. Inhibition of the RANKL 
inhibits osteoclast maturation and activity, consequently reducing the incidence of skeletal-
related events (Figure 4) [Brown 2012]. 
 
 
Figure 4. The effects of denosumab [Brown 2012] 
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In addition to its excellent effect on the underlying disease, denosumab may also result in severe 
side effects in the mandible or in the maxilla. In the literature, osteonecrosis of the jaws resulting 
from denosumab treatment is defined as DRONJ (denosumab-related osteonecrosis of the jaw) 
[Kyrgidis 2011]. 
Due to the long treatment period of the underlying disease, bisphosphonates and denosumab 
are often used consecutively or concomitantly in the same patient, which significantly increases 
the likelihood of developing osteonecrosis [Krestan 2016][Limones 2020]. Osteonecrosis due 
to the use of bisphosphonates, RANKL inhibitors, or their combined use is called as ARONJ 
(antiresorptive agent related osteonecrosis of the jaws) [Hellstein 2014][Shibahara 2019]. 
 
1.4.3. Pharmacology of tyrosine kinase inhibitors 
Tyrosine-kinases (TKs) are enzymes that play an important role in modulating growth factors 
and signaling molecules. They increase cell growth and proliferation, which promotes the 
formation of metastases. Tyrosine kinase inhibitors (TKIs) effectively inhibit TK enzyme 
activity and block the overexpression of excitatory molecules in tumor cells [Hartmann 2009]. 
Vascular endothelial growth factor receptors (VEGFR), epidermal growth factor receptors 
(EGFR), platelet-derived growth factor receptors (PDGFR) are the main targets of TKIs. The 
most widely accepted hypothesis in connection with the TKI-related osteonecrosis is their 
antiangiogenic effect, which may block the overexpression of VEGF in tumor cells, but alters 
normal bone remodeling as well [Gharwan 2015]. To date, osteonecrosis of the jaws has been 
described in association with eight different tyrosine-kinase inhibitors. Increasing number of 
sunitinib- [Fleissig 2012] [Soós 2015], sorafenib- [Garuti 2016], cabozantinib- [Marino 2015], 
regorafenib-  [Antonuzzo 2016], imatinib- [Viviano 2017], axitinib- [Patel 2017], pazopanib- 
[Jung 2017] and dasatinib-related [Abel Mahedi Mohamed 2018] osteonecrosis of the jaws 
were reported in the recent years.  
VEGF induces angiogenesis in vivo and plays a key role in bone angiogenesis. Two sets of 
opposing molecules regulate angiogenesis under homeostatic condition. The balance of the 
proangiogenic (e.g. VEGF) and antiangiogenic (e.g. thrombospondin-1) factors ensure the 
normal (neo)vascularisation of the human body. In tumorous lesions, the balance is disrupted 
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and shifted towards angiogenesis [Rajabi 2017]. VEGF is considered an important factor of 
angiogenesis in tumor cells, therefore, blocking VEGF may have an anticancer role. 
Bevacizumab is a human recombinant monoclonal antibody against VEGF, which binds 
specifically to VEGF molecules and effectively ceases the angiogenesis [Guarneri 2010]. This 
drug is usually prescribed in lung, breast, colorectal and ovarian cancer. Wound healing  
complications occur frequently during treatment [Magremanne 2012]. Several authors reported 
bevacizumab-related osteonecrosis with or without a concomitant bisphosphonate treatment 
[Christodoulou 2008][Estilo 2008][Serra 2009].  
Aflibercept is composed of extracellular domains of human VEGF receptor and specific portion 
of human immunoglobulin. These molecules effectively bind to VEGFs and behave like a trap 
for them. This interaction blocks vascular growth and decreases vascular permeability in the 
tumor [Siu-Chung Chu 2009]. In recent years, case reports of aflibercept related MRONJ have 
appeared in the literature [Mawardi 2016][Ponzetti 2016]. 
 
 1.4.4. Pharmacology of mTOR inhibitors        
The mTOR (mammalian target of rapamycin) is a pathway, which plays an important role in 
the regulation of bone turnover. Different bone cell populations are regulated by mTOR 
signaling, which results in changes in bone remodeling [Shen 2017]. Inhibiting of mTOR 
reduces VEGF production and release, thus successfully blocks angiogenesis in malignancies 
[Dowling 2010]. This process could be responsible for the delayed progression of bone 
metastases and developing mTOR-associated osteonecrosis of the jaws. [Fusco 2016][Nifosi 
2019][Yamamoto 2017]. 
 
1.4.5. Pharmacology of CTLA-4 inhibitors       
The human monoclonal antibody ipilimumab was developed against cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4). CTLA-4 molecules are expressed by activated  T-lymphocytes 
and suppressor T-lymphocytes. After binding to antigen presenting target cells these molecules 
may reduce T-cell dependent immune response [Langer 2007].  According to Kong et al., the 
systemic activation of T-cells implies the production of OPGL (osteoprotegerin ligand), whose 
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corresponding receptor (RANK) is expressed on mature osteoclasts. The interaction between 
OPGL and RANK leads to osteoclastogenesis and resultant bone loss [Kong 1999]. Only a few 
cases of CTLA-4 induced osteonecrosis are reported in the literature; this is probably explained 
by the fact that ipilimumab treatment is usually short-term. [Owosho 2015]. 
 
1.5. Epidemiology of  MRONJ         
The incidence and prevalence of MRONJ show an increasing trend due to the broadened 
indications, the increased number of patients, the unexpected interactions and synergistic 
effects between different groups of drugs (bisphosphonate - denosumab, bisphosphonate - 
VEGF inhibitors, denosumab - VEGF inhibitors) [Sivolella 2013][van Cann 2018]. Only a few 
single- or multicenter, nationwide large cohorts study has been published  in this field, but some 
of these have had methodological limitations, including the lack of standardized case 
definitions, absence of information on patients characteristics and the scarcity of comparable 
data [Bamias 2005][Chaurand-Lara 2019][Gliklich 2009][Rogers 2015][Vescovi 2011][Yuh 
2014]. Many authors agree that data reported in the literature tend to underestimate the real 
incidence and prevalence [Fusco 2016][Galis 2017]. The incidence of the disease may vary 
widely depending on the type of bisphosphonate(s) used, route of administration (iv / orally), 
cumulative dose, underlying disease and comorbidities, concomitant medication therapies and 
surgical interventions [Ghidini 2017][Khan 2017][Otto 2012][Park 2012][Ruggiero 2006].  
A retrospective observational study analyzed the socioeconomic and medication data of 236 
207 Hungarian bisphosphonate users and revealed the estimated incidence of BRONJ in 
Hungary.  Accordingly, the incidence of BRONJ among bisphosphonate users is 0.9% in 
patients with malignancy and 0.1% in patients with non-malignant diseases, and the odds ratio 
(OR) to develop BRONJ was 9.7 (95% CI) between them [Veszelyné 2019]. 
The current literature distinguishes between “low-risk” and “high-risk” patients in terms of the 
likelihood of developing MRONJ.  In general, there is a lower risk of developing osteonecrosis 
in cases of benign underlying disease, oral administration, low cumulative drug dose, lack of 
comorbidities, lack of concomitant drug therapy, good oral hygiene, and adequate patient 
compliance. Factors contributing to the development of MRONJ include underlying 
malignancy, intravenous drug administration, high cumulative dose, long-term drug use, 
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concomitant use of drugs with different attack points, poor oral hygiene, poorly fitting dentures, 
and inadequate compliance [Aghaloo 2015][McGowan 2018][Vereb 2020]. 
Diagnosis and staging are established based on clinical and radiological findings. Differential 
diagnostically, MRONJ should be differentiated from osteomyelitis, osteoradionecrosis and 
metastatic bony lesions. The main purposes of radiological examinations are to assess the extent 
of osteonecrosis, to facilitate individual surgical treatment planning, to follow up cases and to 
evaluate prognosis [Tsuchimochi 2019]. The pathogenesis of MRONJ is not fully elucidated 
yet,  effective and reliable therapy is not currently available, consequently. Treatment options 
include prevention of the disease, delaying or blocking progression, conservative, surgical and 
complementary therapies of soft and hard tissues [Janovszky 2014] [Ramaglia 2018]. 
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II.  Objectives  
 
To the author's best knowledge, no comprehensive nationwide epidemiological study has 
previously been performed in Hungary among BRONJ  patients. The main objectives of the 
study are detailed below: 
 
1) nationwide retrospective and prospective data collection of symptomatic BRONJ 
patients in Hungary 
2) epidemiological description of the gender and age distribution of the involved patients  
3) investigation of underlying and concomitant diseases potentially related to the 
development of the disease 
4) examination of the type, concentration and route and frequency of administration of  
bisphosphonates causing BRONJ 
5) analysis of triggering factors of osteonecrosis of the jaws 
6) investigating the relationships between disease severity and the localization and extent 
of necrosis 
7) identification of associations between disease severity and environmental effects 
 
 
 
 
 
 
 
 
 
20 
III.  Material and methods  
3.1. Ethical permission  
In 2012, following the approval of the local Scientific and Research Ethics Committee of the 
Medical Research Council (license number: 17773/2012/EKU 320/PI/12.) an online 
spreadsheet-based questionnaire and database have been set up and made available for non-
profit use to voluntary researchers and clinicians in Hungary and Slovakia.  
 
3.2. Data collection 
The questionnaire has been made available to cooperating maxillofacial units. Seven 
maxillofacial units from Hungary and one from Slovakia joined the study. Altogether 15 
colleagues participated in the data collection. Patients were selected and excluded based on 
well-defined criteria for the study. 
Inclusion criteria of the study were determined as follows: 
1)     Previous or current BP treatment regardless of drug type, dose or route of  
 administration 
2)     Consecutive or concomitant BP treatment with different bisphosphonate agents 
3)    Intra- or extraoral lesion following or after bisphosphonate therapy 
Exclusion criteria of the study were described below: 
1)  Asymptomatic patients with previous or current bisphosphonate treatment 
2)  Symptomatic patients consecutive and/or concomitant combined antiresorptive and  
antiangiogenic therapies 
3)  Patients with previous or undergoing radiation therapy of head and neck region 
Data have been collected on gender, age on onset of the BRONJ, underlying and concomitant 
diseases, medical and dental history, smoking and alcohol consumption, type of bisphosphonate 
taken, treatment duration, frequency and route of administration, presumed trigger factors, 
clinical stage of disease, location and extent of lesions. 
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3.3. Data processing   
To achieve the purposes of the study a free-accessible Google Sheets (Google LLC, CA, USA) 
was used. Google Sheets is a spreadsheet program which is available as a web and mobile 
application  for each platform. It has a user’s interface which may easily be adapted to the 
needs of the survey. The web based data collection system enables not only detailed data 
collection but also the analysis of the data gained.  
This system is suitable for controlling access permissions and user restrictions in different 
levels. These properties allowed easy real-time collaboration between multiple users working 
on the same document at the same time regardless of distance. Further advantages of the 
applied data collection system are the following: 
1. Easy retrieval and updating of data 
2. (Common) database eliminates duplicate information 
3. Increase efficiency and data consistency 
4. Automatic backup prevents accidental data loss 
5. Data entries and edits are tracked by admin(s) 
6. Data integrity and portability are assured between platforms 
7. Only the bandwidth of the network limits the speed of data transmission 
8. Information security 
A detailed dental and medical history was recorded with regard to previous and current chronic 
diseases. Clarification of triggering factors during the development of osteonecrosis has 
received special attention during retrospective data collection. To determine the location and 
extent of the osteonecrotic lesions both jaws were divided into 5 regions (right molar, right 
premolar, frontal, left premolar, left molar). If more than one region were affected by the 
osteonecrosis, each was taken into consideration. 
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3.4. Statistical analysis 
Statistical analysis was performed with the Statistical Program for Social Sciences version 23.0 
for Windows (SPSS, Chicago, IL, USA). A p-value of less than 0.05 was interpreted to imply 
statistical significance. Means and standard deviations (SD) were calculated. Unpaired student's 
t-test was used for evaluation of statistical significance. Pearson Chi-square test was performed 
to examine the relationships between different biological variables.  
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IV.  Results  
The data of 180 symptomatic BRONJ cases have been recorded during the data collection 
period (from 2012-2016). The number of reported cases decreased from year to year; 64 
patients, 41 patients, 34 patients, 23 patients, 18 patients respectively. Full data were obtained 
for 148 (82.2%) patients. In 32 cases (17.8%) data collection was incomplete. The data on age, 
sex, underlying disease, method of drug administration, staging were complete in all cases. All 
data were included in the statistical analysis. 
 
4.1.  Age and gender distribution         
There was a female predominance in the distribution of BRONJ. 122 women (67.8%) and 58 
men (32.2%) were  affected. Male-to-female ratio was 1:2.1, this correlates well with the results 
of other authors. (Table 2) 
The mean age at the time of the diagnosis was 66.80 years; 66.22 years in women (range 37-85 
years; SD 10.29 years) and 68.02 years in men (range 42-89 years; SD 9.33 years). There was 
no significant difference between the ages of males and females (p=0.246). Patients suffering 
from non-malignant diseases (osteoporosis, rheumatoid arthritis) were generally older (n=36; 
mean 68.57 years; range 38-84 years, SD 9.79 years) than patients with malignant disease 
(n=140; mean 66.32 years; range 37-89 years, SD 9.43 years). 
Within the malignant group renal cancer patients were generally younger (n=13; mean 62.92 
years; range 51-77 years, SD 8.45 years) than the rest of the group (n=127; mean 66.67 years; 
range 37-89 years, SD 9.49 years) but the difference was not significant (p=0.153).  Breast 
cancer patients were only slightly younger (n=66; mean 64.68 years; range 37-85 years, SD 
10.16 years) but the age difference was statistically significant (p=0.045) when compared with 
the rest of the group (n=74; mean 67.86 years; range 48-89 years, SD 8.49 years).  
The mean age of multiple myeloma and lung cancer patients were 67.62 (n=16; range 57-80 
years, SD 6.9 years) and 65.00 (n=7; range 48-81 years, SD 10.77 years), respectively. Prostate 
cancer patients (n=30; mean 71.57 years; range 61-89 years, SD 7.00 years) were significantly 
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older (p=0.000075) than the other malignant cases (n=110; mean 64.93 years; range 37-85 
years, SD 9.53 years). 
 
  Number Female          Percent Male              Percent 
Vereb 2020 180 122 67.8% 58 32.2% 
Otto 2012 126 92 73.0% 34 27.0% 
Diniz-Freitas 
2012 
20 19 95% 1 5% 
Schubert 2011 258 175 67.8% 83 32.2% 
Kos 2010 34 19 55.9% 15 44.1% 
Mavrokokki 
2007 
114 63 55% 51 45% 
Summary 732 490 66.9 % 242 33.1 % 
Table 2. Male-female ratio by different authors 
 
4.2. Underlying diseases      
The vast majority of BRONJ cases occurred in patients with malignant diseases (n=140; 
77.8%). 34 patients (18.9%) received bisphosphonate for osteoporosis; 2 patients (1.1%) were 
diagnosed with rheumatoid arthritis. In 4 cases (2.2 %) the reasons for treatment remained 
unknown because of the nature of retrospective studies. (Table 3) 
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Underlying disease n mean min max SD 
Malignant Breast cc. 66 64.68 37 85 10.16 
 Prostate cc. 30 71.57 61 89 7.00 
 Multiple myeloma 16 67.62 57 80 6.09 
 Renal cc. 13 62.92 51 77 8.45 
 Lung cc. 7 65.00 48 81 10.77 
 Gastrointestinal cc. 5 66.80 54 80 - 
 Other cc. 3 62.00 53 75 - 
                        Total malignant 140 62.32 37 89 9.43 
Benign Osteoporosis 34 70.31 42 84 9.79 
 Rheumatoid arthritis 2 39 38 40 - 
                         Total benign 36 68.57 38 84 - 
Summary 176 66.80 37 89 - 
Table 3. Age distribution based on known underlying disease (n=176) 
 4.3. Comorbidities           
Data of comorbidities were complete in 162 (90%) cases. High blood pressure and/or cardiac 
disease was reported in 75 (46.29%) cases. Nineteen (11.72%) patients suffered from diabetes 
mellitus. Chronic obstructive pulmonary disease (COPD) and/or asthma were diagnosed in 6 
(3.70%) cases. Concomitant renal, hepatic and gastrointestinal diseases were reported in 11 
(6.79%), 7 (4.32%) and 9 (5.56%) patients, respectively. 
4.4. Types of bisphosphonates and routes of administration 
Fifty-two individuals (28.9%) were given oral bisphosphonates alone. In this group ibandronic 
acid (n=19; 36.6%) and alendronic acid (n=18; 34.6%) were the most frequently used agents, 
followed by clodronic acid (n=9; 17.3%) and risedronic acid (n=6; 11.5%). (Table 4)  
26 
Oral bisphosphonate Benign diseases Malignant diseases Summary 
alendronate 17 1 18 
ibandronate 2 17 19 
clodronate 4 5 9 
risedronate 6 - 6 
Summary 29 23 52 
 Table 4. BRONJ cases caused by oral bisphosphonates 
Number of bisphosphonate 
infusions 
zoledronate 
(combined) 
zoledronate 
(single) 
ibandronate pamidronate 
1-6 x - 29 - - 
7-12 x 1 17 5 - 
13-18 x - 11 1 - 
19-24 x 3 12 3 - 
25-30 x 1 6 1 - 
31-36 x - 7 - - 
37-42 x - 2 - - 
43-48 x - 6 1 - 
>48 x 1 20 - 1 
Summary 6 110 11 1 
Table 5. Development of osteonecrosis depending on the type of intravenous bisphosphonate 
and the number of infusions administered 
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In the vast majority of the cases, bisphosphonates were administered intravenously alone 
(n=106; 58.9%) or in combination with oral drugs (n=22; 12.2%). A total of 128 patients 
(71.1%) received intravenous bisphosphonate therapy.  
Intravenous zoledronic acid was associated with the highest risk of BRONJ, 110 patients 
(61.1%) were treated with this drug alone, or in combination with other agents (n=6; 3.3%). 
Altogether 116 patients (64.4% of all patients; 90.6% in the intravenously treated group) were 
administered intravenous zoledronic acid. (Table 5) 
Results of the Pearson Chi-square test showed a statistically significant relationship (p=0.023) 
between the severity of stages (Stage 1: mild versus Stage 2+3:serious) and the administration 
method. (Table 6) 
 
                                                             Staging                                            Total 
                                  Stage1              Stage 2   Stage 3 
Intravenous                  14                  57                   35                          106 
                                      13,2%               53,8%            33,0%                        100,0% 
Both                               7              11          4                              22 
                                      31,8%               50,0%            18,2%                        100,0% 
Oral                               15                      28            9                      52 
                                      28,8%               53,8%            17,3%                        100,0% 
Total                              36        96                   48                  180 
                                      20,0%               53,3%             26,7%                       100,0% 
 Table 6. The correlation between the severity of ONJ and the route of administration. 
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4.5. Triggering factors          
Presumed triggering factors were reported in 167 cases. Dental extraction was the most 
common predisposing event (n=121; 72.4%). A further 6 patients (3.6%) had previous other 
dentoalveolar surgery (implant placement, periodontal surgery). Pre-existing inflammatory 
diseases such as periodontal and/or periapical pathology were present in 19 cases (11.4%). 
Denture use was thought to be the main trigger factor in 12 cases (7.2%).  BRONJ was 
considered of spontaneous origin in 9 cases (5.4%). 
4.6. Staging of BRONJ   
At the time of the first clinical examination 36 cases (20.0%) were categorized as stage 1.  The 
majority of the patients (n=96; 53.3%) were diagnosed as stage 2. Forty-eight cases (26.7%) 
were classified as stage 3 with extraoral fistula, pathological fracture, involvement of the 
maxillary sinus or the inferior border or the ramus of the mandible. The underlying disease and 
its malignant or benign nature were determined in 176 cases. There were 36 benign cases, the 
distributions of stages were as follows: stage 1: 36.1% (n = 13), stage 2: 47.2% (n = 17), stage 
3 16.7% (n = 6) respectively.  From the 140 underlying malignancies, 23 (16.4%) were 
classified in stage 1, 77 cases (55.0%) ranked as stage 2 and 40 cases (28.6%) belonged to stage 
3.  
At the time of the first visit, more severe stages (2-3) occured in a higher proportion of patients 
with malignancies compared to patients with benign conditions (stage 1:  36.1 % vs. 16.4 %, 
stage 2 : 47.2 % vs 55.0 %, stage 3: 16.7 % vs 28.6% )  As stage worsened, the proportion of 
malignant cases increased significantly compared to the number of benign cases (stage 1 -  
1:1.77, stage 2 - 1:4.53, stage 3 - 1:6.66) A significant difference was found between the benign 
and malignant groups (Pearson Chi-Square test p=0.026). Although much more women than 
men are affected by BRONJ; in stage 3 the number of female and male patients were almost 
equal, 26 (54.2%) and 22 (45.8%) respectively.  
4.7. Localization of osteonecrosis  
194 jaws were affected by bisphosphonate-related osteonecrosis of the jaws altogether.  In 124 
patients (68.9%) only the mandible, in 42 patients (23.3%) only the maxilla; in 14 cases (7.8%) 
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both jaws were affected. Altogether 304 regions were affected by BRONJ in 180 patients; 213 
regions (70.1%) in the mandible and 91 regions (29.9%) in the maxilla. The most common sites 
of osteonecrosis were the molar (n=98; 32.2%) and the premolar regions of the mandible (n=82; 
27%), followed by the upper molar (n=36; 11.8%) and premolar regions (n=35; 11.5%). The 
lower and upper front regions were affected in 33 (10.9%) and 20 (6.6%) cases, respectively. 
(Figure 5.) In terms of localization, the results correlate well with the results published by Otto 
et al [Otto 2012]. 
 
 
Figure 5. Localizations of BRONJ by regions (Abbreviations: URM-upper right molar, URPm-
upper right premolar, UFr-upper frontal, ULPm-upper left premolar, ULM-upper left molar, LRM-
lower right molar, LRPm-lower right premolar, LFr-lower frontal, LLPm-lower left premolar, LLM-
lower left molar). 
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V.  Discussion   
BRONJ is a relatively newly recognized condition that has generated great interest not only 
amongst oral and maxillofacial surgeons but also in other medical and research communities. 
Our study found female predominance among BRONJ patients (female 67,8 %, male: 32,2 %; 
male to female ratio 1 : 2.1) which is in line with the results of Otto and Schubert [Otto 
2012][Schubert 2012], but slightly higher than in Kos’ and Mavrokokki’s publications [Kos 
2010][Mavrokokki 2007]. Female-to-male ratio of 8:1 were published by Pazianas [Pazianas 
2007]. 
77.8% of the patients suffered from an underlying malignant disease, this proportion closely 
correlates with Mavrokokki’s result, who referred to 72% of bone malignancies among their 
patients [Mavrokokki 2007]. The mean age of the benign group (68.57 years) is not significantly 
higher than the age of the malignant group (66.32 years). Within the malignant group, BRONJ 
developed at a significantly higher age in prostate cancer patients compared to the remainder 
of the group. BRONJ was diagnosed at a significantly younger age in breast cancer patients 
compared to the rest of the malignant group. Although in our investigation there were only two 
rheumatoid arthritis patients  (mean: 39.0 years SD: 1 years); there is still a surprisingly huge 
age difference when it is compared to the results of Di Fede (n=18 mean: 68 years SD: 8 years) 
[Di Fede  2016]. 
Gabbert’s examination pointed out that osteonecrosis free survival in single bisphosphonate 
users was significantly longer in pamidronate-treated patients than in zoledronate or 
ibandronate users [Gabbert 2015]. In our study, from the intravenous group 127 of 128 patients 
(99.2%) were administered zoledronate and/or ibandronate and only one patient (0,8%) was 
diagnosed with BRONJ following pamidronate treatment. Our results also prove that the route 
of administration has a significant (p=0.023) association with the severity of the osteonecrosis.  
According to Thumbigere-Math et al. increased cumulative doses and long-term 
bisphosphonate treatment are the most important risk factors for osteonecrosis, but the type of 
bisphosphonate may also play a role in the incidence of osteonecrosis; our results confirm these 
findings [Thumbigere-Math 2012]. 
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According to the literature, the mandible is affected  in 64 to 70.6%; the maxilla is involved in 
18.3 to 27%. BRONJ was present in both jaws in 9 to 11.1%. Our findings (mandible 70.1%, 
maxilla 23.3%, both jaws 7.8%) correlate well with these results. There is a characteristic 
distribution of osteonecrosis with a predilection for the molar and premolar region in both jaws, 
just as it was pointed out by Otto et al [Mavrokokki 2007][Otto 2012]. 
At the time of the diagnosis the majority of the patients (53.3%) were categorized as stage 2; 
20.0% and 26.7% were classified as stage 1 and stage 3, respectively. These findings are similar 
to those of Schiodt et al (stage 1: 26%; stage 2: 58%; stage 3: 10%; unknown: 3%; resolved: 
2%) [Schiodt 2018]. Although much more women than men are affected by BRONJ, their 
number in stage 3 is nearly the same (26 and 22, respectively). The ratio of malignant cases to 
benign cases increased significantly (p=0,026) as the stage worsened (stage 1 -  1:1.77, stage 2 
- 1:4.53, stage 3 - 1:6.66). 
The evolution of cloud-based information technology has dramatically changed data collection 
and analysis for scientific purposes. To the best of our knowledge our study is the first one that 
has collected data on BRONJ patients from multiple centers with this method. 
Despite the many advantages offered by cloud-based technology our study also has some 
pitfalls. The participation has been voluntary and this has probably resulted in under-reporting; 
therefore our data are not informative about the incidence of BRONJ. The relatively high 
number of incomplete reports is surprising but this can be explained by the fact that the online 
questionnaire was not filled out at the time of the patient’s examination and later data were not 
found in the documents.  
The number of patients reported in this study is high compared to other single-center or even 
multicenter studies but the average number of patients reported per center per year is less than 
6 in the 4-year study period. 
The decreasing trend of the number of new patients reported  per year probably reflects that 
voluntary researchers have lost their initial enthusiasm, but better patient management, early 
diagnosis and state-of-the-art prevention techniques might also played an important role. A 
sample size of 180 BRONJ cases is considered statistically significant but data were not always 
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sufficient to reach statistically reliable conclusions when the patients were classified into 
groups. More patients are needed to improve the power of the study. A multicenter registry that 
collects systematic information on epidemiological data is essential to increase our knowledge 
of BRONJ. Cloud-based information collection is an ideal tool for this purpose. The online and 
voluntary nature of the current study may slightly diminish the accuracy of the results but the 
increasing number of patients involved will improve statistical conclusions.  
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VI.  Summary of new findings 
 
1) We have successfully introduced a cloud-based multicentric real-time data collection 
method to obtain population-wide epidemiological data on a rare but serious side effect. 
2) According to our best knowledge, this examination was the first descriptive 
epidemiological analysis on a Central European population in terms of BRONJ. 
3) Prostate cancer patients (n=30; mean 71.57 years; range 61-89 years, SD 7.00 years) 
were significantly older (p=0.000075) than the other malignant cases (n=110; mean 
64.93 years; range 37-85 years, SD 9.53 years) 
4) Breast cancer patients were only slightly younger (n=66; mean 64.68 years; range 37-
85 years, SD 10.16 years) but the age difference was statistically significant (p=0.045) 
when compared with the rest of the group (n=74; mean 67.86 years; range 48-89 years, 
SD 8.49 years).  
5) We have demonstrated that if the stage worsened, the proportion of malignant cases 
increased significantly compared to the number of benign cases (stage 1 -  1:1.77, stage 
2 - 1:4.53, stage 3 - 1:6.66) A significant difference has been found between the benign 
and malignant groups (p=0.026). 
6) We have found statistically significant (p=0.023)  correlation between the severity of 
stages (Stage 1: mild cases versus Stage 2+3: serious cases) and the administration 
method (oral versus intravenous).  
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